hal.structure.identifier | Anticancer Fund [Strombeek-Bever, Belgium] | |
dc.contributor.author | PANTZIARKA, Pan | |
hal.structure.identifier | Nature Reviews Clinical Oncology [London, UK] | |
dc.contributor.author | HUTCHINSON, Lisa | |
hal.structure.identifier | Metronomics Global Health Initiative | |
hal.structure.identifier | Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM] | |
hal.structure.identifier | Centre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2] | |
dc.contributor.author | ANDRÉ, Nicolas | |
hal.structure.identifier | Modélisation Mathématique pour l'Oncologie [MONC] | |
hal.structure.identifier | Institut de Mathématiques de Bordeaux [IMB] | |
dc.contributor.author | BENZEKRY, Sébastien | |
hal.structure.identifier | European Institute of Oncology [Milan] [ESMO] | |
dc.contributor.author | BERTOLINI, Francesco | |
hal.structure.identifier | Malabar Cancer Center | |
dc.contributor.author | BHATTACHARJEE, Atanu | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | CHIPLUNKAR, Shubhada | |
hal.structure.identifier | Massachusetts General Hospital [Boston] | |
dc.contributor.author | DUDA, Dan | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | GOTA, Vikram | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | GUPTA, Sudeep | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | JOSHI, Amit | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | KANNAN, Sadhana | |
hal.structure.identifier | Sunnybrook Research Institute [Toronto] [SRI] | |
dc.contributor.author | KERBEL, Robert | |
hal.structure.identifier | Dana-Farber Cancer Institute [Boston] | |
dc.contributor.author | KIERAN, Mark | |
hal.structure.identifier | European Institute of Oncology [Milan] [ESMO] | |
dc.contributor.author | PALAZZO, Antonella | |
hal.structure.identifier | PRA Health sciences [Mumbai] | |
dc.contributor.author | PARIKH, Aparna | |
hal.structure.identifier | Centre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2] | |
hal.structure.identifier | Metronomics Global Health Initiative | |
dc.contributor.author | PASQUIER, Eddy | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | PATIL, Vijay | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | PRABHASH, Kumar | |
hal.structure.identifier | Technion - Israel Institute of Technology [Haifa] | |
dc.contributor.author | SHAKED, Yuval | |
hal.structure.identifier | Helen DeVos Children’s Hospital [Grand Rapids, MI, USA] | |
dc.contributor.author | SHOLLER, Giselle | |
hal.structure.identifier | Masaryk University [Brno] [MUNI] | |
dc.contributor.author | STERBA, Jaroslav | |
hal.structure.identifier | Boston University [Boston] [BU] | |
dc.contributor.author | WAXMAN, David | |
hal.structure.identifier | Metronomics Global Health Initiative | |
hal.structure.identifier | Tata Memorial Centre | |
dc.contributor.author | BANAVALI, Shripad | |
dc.date.accessioned | 2024-04-04T03:13:11Z | |
dc.date.available | 2024-04-04T03:13:11Z | |
dc.date.issued | 2016 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/193934 | |
dc.description.abstractEn | The 5th Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th – 8th May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and pre- dictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies. | |
dc.language.iso | en | |
dc.publisher | ecancer Global Foundation | |
dc.subject.en | cancer | |
dc.subject.en | anti-angiogenics | |
dc.subject.en | drug repurposing | |
dc.subject.en | LMIC | |
dc.subject.en | metronomic chemotherapy | |
dc.title.en | Next generation metronomic chemotherapy - report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6 - 8 May 2016, Mumbai | |
dc.type | Article de revue | |
dc.identifier.doi | 10.3332/ecancer.2016.689 | |
dc.subject.hal | Sciences du Vivant [q-bio]/Cancer | |
bordeaux.journal | Ecancermedicalscience | |
bordeaux.volume | 10 | |
bordeaux.hal.laboratories | Institut de Mathématiques de Bordeaux (IMB) - UMR 5251 | * |
bordeaux.institution | Université de Bordeaux | |
bordeaux.institution | Bordeaux INP | |
bordeaux.institution | CNRS | |
bordeaux.peerReviewed | oui | |
hal.identifier | hal-01392473 | |
hal.version | 1 | |
hal.popular | non | |
hal.audience | Internationale | |
hal.origin.link | https://hal.archives-ouvertes.fr//hal-01392473v1 | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Ecancermedicalscience&rft.date=2016&rft.volume=10&rft.au=PANTZIARKA,%20Pan&HUTCHINSON,%20Lisa&ANDR%C3%89,%20Nicolas&BENZEKRY,%20S%C3%A9bastien&BERTOLINI,%20Francesco&rft.genre=article | |